Escient is a clinical-stage pharmaceutical company focused on discovering and developing first-in-class therapies to address serious, unserved medical needs. The company is led by an experienced team with specific expertise in GPCR drug discovery and development. Escient's pipeline consists of two novel antagonists targeting MrgprX4 for the treatment of cholestatic pruritis and MrgprX2 for mast-cell mediated disorders.